Package: drugdevelopR 1.0.2
Lukas D. Sauer
drugdevelopR: Utility-Based Optimal Phase II/III Drug Development Planning
Plan optimal sample size allocation and go/no-go decision rules for phase II/III drug development programs with time-to-event, binary or normally distributed endpoints when assuming fixed treatment effects or a prior distribution for the treatment effect, using methods from Kirchner et al. (2016) <doi:10.1002/sim.6624> and Preussler (2020). Optimal is in the sense of maximal expected utility, where the utility is a function taking into account the expected cost and benefit of the program. It is possible to extend to more complex settings with bias correction (Preussler S et al. (2020) <doi:10.1186/s12874-020-01093-w>), multiple phase III trials (Preussler et al. (2019) <doi:10.1002/bimj.201700241>), multi-arm trials (Preussler et al. (2019) <doi:10.1080/19466315.2019.1702092>), and multiple endpoints (Kieser et al. (2018) <doi:10.1002/pst.1861>).
Authors:
drugdevelopR_1.0.2.tar.gz
drugdevelopR_1.0.2.zip(r-4.5)drugdevelopR_1.0.2.zip(r-4.4)drugdevelopR_1.0.2.zip(r-4.3)
drugdevelopR_1.0.2.tgz(r-4.4-any)drugdevelopR_1.0.2.tgz(r-4.3-any)
drugdevelopR_1.0.2.tar.gz(r-4.5-noble)drugdevelopR_1.0.2.tar.gz(r-4.4-noble)
drugdevelopR_1.0.2.tgz(r-4.4-emscripten)drugdevelopR_1.0.2.tgz(r-4.3-emscripten)
drugdevelopR.pdf |drugdevelopR.html✨
drugdevelopR/json (API)
NEWS
| # Install 'drugdevelopR' in R: |
| install.packages('drugdevelopR', repos = c('https://sterniii3.r-universe.dev', 'https://cloud.r-project.org')) |
Bug tracker:https://github.com/sterniii3/drugdevelopr/issues
Last updated 22 hours agofrom:65700d553b. Checks:OK: 3 NOTE: 4. Indexed: yes.
| Target | Result | Date |
|---|---|---|
| Doc / Vignettes | OK | Nov 22 2024 |
| R-4.5-win | NOTE | Nov 22 2024 |
| R-4.5-linux | NOTE | Nov 22 2024 |
| R-4.4-win | NOTE | Nov 22 2024 |
| R-4.4-mac | NOTE | Nov 22 2024 |
| R-4.3-win | OK | Nov 22 2024 |
| R-4.3-mac | OK | Nov 22 2024 |
Exports:d3_skipII_ttedbivanormdrugdevelopRdrugdevelopResultEd3_LEd3_L2Ed3_REd3_R2Ed3_tteEn3_binary_LEn3_binary_L2En3_binary_REn3_binary_R2En3_normal_LEn3_normal_L2En3_normal_REn3_normal_R2Epgo_binary_L2Epgo_binary_R2Epgo_L2Epgo_normal_L2Epgo_normal_R2Epgo_R2Epgo_tteEpgo23Epgo23_binaryEpgo23_normalEPsProg_binary_LEPsProg_binary_L2EPsProg_binary_REPsProg_binary_R2EPsProg_LEPsProg_L2EPsProg_multiple_normalEPsProg_multiple_tteEPsProg_normal_LEPsProg_normal_L2EPsProg_normal_REPsProg_normal_R2EPsProg_REPsProg_R2EPsProg_tteEPsProg2EPsProg2_binaryEPsProg2_normalEPsProg23EPsProg23_binaryEPsProg23_normalEPsProg3EPsProg3_binaryEPsProg3_normalEPsProg4EPsProg4_binaryEPsProg4_normalEss_binaryEss_multiple_normalEss_multiple_tteEss_normalEss_ttefmaxfminoptimal_biasoptimal_bias_binaryoptimal_bias_normaloptimal_binaryoptimal_multiarmoptimal_multiarm_binaryoptimal_multiarm_normaloptimal_multiple_normaloptimal_multiple_tteoptimal_multitrialoptimal_multitrial_binaryoptimal_multitrial_normaloptimal_normaloptimal_tteos_ttepgo_binarypgo_multiple_normalpgo_multiple_ttepgo_normalpgo_tteposp_normalprior_ttePsProg_binaryPsProg_normalPsProg_ttepwss_binaryss_normalss_tteutility_binary_Lutility_binary_L2utility_binary_Rutility_binary_R2utility_Lutility_L2utility_multiarmutility_multiarm_binaryutility_multiarm_normalutility_multiple_normalutility_multiple_tteutility_normal_Lutility_normal_L2utility_normal_Rutility_normal_R2utility_Rutility_R2utility_tteutility2utility2_binaryutility2_normalutility23utility23_binaryutility23_normalutility3utility3_binaryutility3_normalutility4utility4_binaryutility4_normal
Dependencies:clicodetoolscubaturedigestdoParallelexpmfansiforeachgenericsglueiteratorslatticelifecyclemagrittrMASSMatrixmsmmvtnormpillarpkgconfigprogressrRcpprlangsurvivaltibbleutf8vctrs
Bias adjustment - methods for discounting of phase II results
Rendered fromBias_adjustment.Rmdusingknitr::rmarkdownon Nov 22 2024.Last update: 2023-12-20
Started: 2022-12-31
Binary outcome variables
Rendered fromBinary_outcomes.Rmdusingknitr::rmarkdownon Nov 22 2024.Last update: 2023-12-20
Started: 2023-03-30
Fixed effect estimates and prior distributions
Rendered fromFixed_and_prior_distributions.Rmdusingknitr::rmarkdownon Nov 22 2024.Last update: 2023-12-20
Started: 2022-12-04
Interpreting the rest of the output
Rendered fromInterpreting_Output.Rmdusingknitr::rmarkdownon Nov 22 2024.Last update: 2023-12-20
Started: 2022-12-13
Introduction to planning phase II and phase III trials with drugdevelopR
Rendered fromIntroduction-to-drugdevelopR.Rmdusingknitr::rmarkdownon Nov 22 2024.Last update: 2023-09-22
Started: 2023-04-18
More parameters to adapt to specific settings
Rendered fromMore_Parameters.Rmdusingknitr::rmarkdownon Nov 22 2024.Last update: 2023-12-20
Started: 2022-12-28
Multiarm - methods for multi-arm programs
Rendered fromMultiarm_Trials.Rmdusingknitr::rmarkdownon Nov 22 2024.Last update: 2023-12-20
Started: 2022-12-31
Multiple - methods for trials with multiple endpoints
Rendered fromMultiple_Endpoints.Rmdusingknitr::rmarkdownon Nov 22 2024.Last update: 2023-12-20
Started: 2022-12-31
Multitrial - methods for programs with several phase III trials
Rendered fromMultitrial.Rmdusingknitr::rmarkdownon Nov 22 2024.Last update: 2023-12-20
Started: 2022-12-31
Package validation
Rendered fromPackage_validation.Rmdusingknitr::rmarkdownon Nov 22 2024.Last update: 2023-12-20
Started: 2023-04-17
Time-to-event outcome variables
Rendered fromTime-to-event_outcomes.Rmdusingknitr::rmarkdownon Nov 22 2024.Last update: 2023-12-20
Started: 2022-12-31
